Differential expression of plasma microRNA‐125b in hepatitis B virus‐related liver diseases and diagnostic potential for hepatitis B virus‐induced hepatocellular carcinoma

Chen, Shanshan; Chen, Hao; Gao, Shanshan; Qiu, Shili; Zhou, Hu; Mu, Yu; Tu, Jiancheng

doi:10.1111/hepr.12739

Cited by 63 publications

(42 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 Meanwhile, because of inadequate sensitivity and the positive predicative value of AFP, AFP determination is also far from being satisfactory. 39,40 In our recruited HCC group, the AFP-positive rates were approximately 55.7% (54/97) using a threshold of 20 ng/mL and were close to the previous reported level. 39 Thus, there is an urgent need for novel biomarkers for HCC.…”

Section: Discussionsupporting

confidence: 85%

Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma

et al. 2019

View full text Add to dashboard Cite

Circular RNAs (circRNAs) have been increasingly revealed to be desirable biomarkers for some tumors, including hepatocellular carcinoma (HCC). Combined with our previous microarray screening results, we aimed to determine the hsa_circ_0028502 and hsa_circ_0076251 expression features in HCC, analyze the relationship between their expression level and clinical and pathological characteristics, and investigate their diagnostic and prognostic values. Our data demonstrated that the hsa_circ_0028502 and hsa_circ_0076251 levels were considerably lower in HCC tissues than in adjacent paracancerous tissues (P < .001). Further study revealed that hsa_circ_0028502 expression levels were related to tumor node metastasis (TNM) stage (P = .015) and that hsa_circ_0076251 expression levels were related to Barcelona Clinic Liver Cancer (BCLC) stage (P = .038), comorbidity with type 2 diabetes mellitus (P = .023) and the presence of serum HbsAg (P = .044). Furthermore, the degree of expression of both hsa_circ_0028502 and hsa_circ_0076251 increased from HCC to liver cirrhosis (LC) to chronic hepatitis (CH). The receiver operating characteristic (ROC) curve demonstrated that hsa_circ_0028502 and hsa_circ_0076251 could serve as fairly accurate markers to distinguish HCC tissues from CH tissues and LC tissues, as well as distinguishing LC tissues from CH tissues. Cox regression analysis showed that low expression of has_circ_0076251 was associated with unfavorable survival rates in HCC (HR = 0.46; 95% CI = 0.22‐0.98; P < .05). These findings implied that hsa_circ_0028502 and hsa_circ_0076251 were potentially valuable biomarkers for HCC diagnosis, whereas hsa_circ_0076251 could be used as a prognostic indicator for HCC.

show abstract

Section: Discussionsupporting

confidence: 85%

Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma

et al. 2019

View full text Add to dashboard Cite

show abstract

“…For example, miR-125b-5p was associated with the biological behavior of HCC and had the diagnostic value of HCC for both Turks and Chinese. As in plasma samples of Chinese patients, it was found to be down-regulated121 whereas in Turks samples, its expression level was up33. For comparison of Egyptian and Chinese, the down-regulation of miR-146a-5p was correlated with HCC carcinogenesis and deterioration in Chinese population103, but in samples of Egyptian patients, it was inverse42.…”

Section: Resultsmentioning

confidence: 92%

“…Chen et al . analyzed the plasma samples from 242 individuals and uncovered that the expression of miR-125b-5p (miR-125b) was significantly down-regulated in HBV-induced HCC (HBV-HCC) patients compared to healthy controls as well as HBV groups without HCC121. Moreover, the low plasma level of miR-125b-5p also reflected the higher possibility of metastasis.…”

Section: Resultsmentioning

confidence: 99%

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Shen

Lin

Yuan

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Hepatocellular Carcinoma (HCC) is one of the most common malignant tumors with high incidence and mortality rate. Precision and effective biomarkers are therefore urgently needed for the early diagnosis and prognostic estimation. MicroRNAs (miRNAs) are important regulators which play functions in various cellular processes and biological activities. Accumulating evidence indicated that the abnormal expression of miRNAs are closely associated with HCC initiation and progression. Recently, many biomarker miRNAs for HCC have been identified from blood or tissues samples, however, the universality and specificity on clinicopathological features of them are less investigated. In this review, we comprehensively surveyed and compared the diagnostic, prognostic, and therapeutic roles of HCC biomarker miRNAs in blood and tissues based on the cancer hallmarks, etiological factors as well as ethnic groups, which will be helpful to the understanding of the pathogenesis of biomarker miRNAs in HCC development and further provide accurate clinical decisions for HCC diagnosis and treatment.

show abstract

“…We excluded 873 additional studies after reading the titles and abstracts. Hence, only 165 studies were used for fulltext assessment; 8 out of the 165 studies were eligible and were ultimately included [18][19][20][21][22][23][24][25]. These included 869 HBV-HCC patients and 1338 non-HCC controls.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

The role of circulating microRNAs for the diagnosis of hepatitis B virus-associated hepatocellular carcinoma with low alpha-fetoprotein level: A systematic review and meta-analysis

Cheng

Xie

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Alpha-fetoprotein (AFP) has been widely used for many years as a serum marker for hepatocellular carcinoma (HCC). However, AFP has been recognized as having poor sensitivity. More and more studies have concluded that circulating microRNAs (miRNAs) might be a promising biomarker that could complement AFP. However, the diagnostic ability of circulating miRNAs has varied among the studies. Therefore, we performed the present meta-analysis to appraise the diagnostic performance of circulating miRNAs as a biomarker for hepatitis B virus-associated HCC (HBV-HCC) patients with low AFP levels. Methods:We performed a systematic review and meta-analysis of the published literature to assess the diagnostic accuracy of circulating miRNAs in differentiating HBV-HCC patients with low AFP levels from non-HCC controls. Results:Circulating miRNAs showed promising potential in the diagnosis of HBV-HCC patients with low AFP levels. In the low-AFP HBV-HCC patients, the area under the curve (AUC) was 0.88 (95% confidence interval [CI]: 0.84-0.90). The pooled sensitivity and specificity were 0.84 (95% CI: 0.78-0.88) and 0.76 (95% CI: 0.69-0.83), respectively. Conclusions:The detection of circulating miRNAs provides a valuable method for the diagnosis of HBV-HCC in patients with low AFP levels.

show abstract

Differential expression of plasma microRNA‐125b in hepatitis B virus‐related liver diseases and diagnostic potential for hepatitis B virus‐induced hepatocellular carcinoma

Abstract: The measurement of plasma-based miR-125b holds promise as a diagnostic marker for HBV-HCC differential diagnosis and for chronic HBV viral infection. Those HBV-infected individuals with increased risk of HCC would be detected early through monitoring the changes in this circulating miRNA.

Cited by 63 publications

References 31 publications

Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma

Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

The role of circulating microRNAs for the diagnosis of hepatitis B virus-associated hepatocellular carcinoma with low alpha-fetoprotein level: A systematic review and meta-analysis

Contact Info

Product

Resources

About